SUTACIMIG

UNII:	2QP8468SQP
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	SUTACIMIG
GSRS Full Record:	2QP8468SQP i

2933972-64-4
H-gamma4 heavy chain anti-F7a humanized (1-448) [VH (Homo sapiens IGHV4-30-2*07 (92.9%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [9.7.15] (26-34.52-58.97-111)) (1-122)-Homo sapiens IGHG4*01 nG4m(a) CH2 L92, G4v5 h P10, G4v10 CH3 L85.1, K88 (CH1 (123-220), hinge 1-12 S10>P (230) (221-232), CH2 L92 (311) (233-342), CH3 F85.1>L (407), R88>K (411) (343-447), CHS K2>del (448)) (123-448)], (136-214')-disulfide with L-kappa light chain humanized anti-F7a (1'-214') [V-KAPPA (Homo sapiens IGKV3D-11*01 (88.8%) -IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; H-gamma4 heavy chain anti-TREML1 humanized (1''-440'') [VH (Homo sapiens IGHV3-74*01 (89.7%) -(IGHD) -IGHJ5*01 (92.9%), CDR-IMGT [8.8.7] (26''-33''.51''-58''.97''-103'')) (1''-114'')-Homo sapiens IGHG4*01 nG4m(a) CH2 L92, G4v5 h P10 (CH1 (115''-212''), hinge 1-12 S10>P (222'') (213''-224''), CH2 L92 (303'') (225''-334''), CH3 (335''-439''), CHS K2>del (440'')) (115''-440'')], (128''-219''')-disulfide with L-kappa light chain, anti-TREML1 humanized (1'''-219''') [V-KAPPA (Homo sapiens IGKV2-24*02 (91.0%) -IGKJ2*01 (100%), CDR-IMGT [11.3.9] (27'''-37'''.55'''-57'''.94'''-102''')) (1'''-112''') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (158'''), V101 (196''')) (113'''-219''')];dimer (228-220'':231-223'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
Immunoglobulin G4 [230-proline,407-leucine,411-lysine,de-C-terminal-lysine], bispecific, anti-(human blood-coagulation factor VIIa) (human-Mus musculus monoclonal 11F2 γ4-chain), disulfide with human-Mus musculus monoclonal 11F2 κ-chain, (228→220′),(231→223′)-bis(disulfide) with immunoglobulin G4 [222-proline,de-C-terminal lysine] anti-(human TREM-like transcript 1 protein) (human monoclonal 0012Hyb γ4-chain) disulfide with human-Mus musculus monoclonal 0012Hyb κ-chain
Sutacimig
immunoglobulin (H-gamma4_L-kappa)_(H-gamma4_L-kappa), anti-[Homo sapiens F7 (coagulation factor 7, blood coagulation factor VII, coagulation serum prothrombin conversion accelerator) activated (F7a, F7A, FVIIa, FVIIA)] and anti-[Homo sapiens TREML1 (triggering receptor expressed on myeloid cells like 1, TREM-like transcript 1, TLT1, TLT-1)], humanized monoclonal antibody, bispecific, bivalent
sutacimig [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

SUTACIMIG

Synonyms and Mappings

Resources